Physician profile
Brian E Cox
NPI 1992017503
$4,596.10
in general payments reported to CMS, 2019-2025
17 companies · $771 in 2025
The $771 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $45.95 · 2021: $1,262 · 2022: $745 · 2023: $678 · 2024: $794 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188 · Entertainment: $54.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.21 |
| Entertainment | $54.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,405.63 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $619.90 | 2019-2025 | Total30, Precision7 |
| Sun Pharmaceutical Industries INC. | $290.18 | 2023-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $177.59 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.98 | 2019-2021 | |
| Visioneering Technologies, INC. | $147.77 | 2025 | |
| Ocular Therapeutix, INC. | $125.00 | 2024 | Dextenza |
| Oyster Point Pharma, INC. | $121.16 | 2023 | Tyrvaya |
| Dompe US, INC. | $116.86 | 2024 | Oxervate |
| Abbvie INC. | $100.38 | 2022 | |
| Optos, INC. | $78.03 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $76.69 | 2022-2025 | Infuse |
| Glaukos Corporation | $71.43 | 2019 | |
| Coopervision INC. | $43.10 | 2024-2025 | Myday Contact Lens |
| Astellas Pharma US INC | $28.28 | 2024 | Izervay |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Kala Pharmaceuticals, INC. | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.